September 14, 2021, the Board of Directors of Travere Therapeutics, Inc. approved the appointment of Sandra Calvin as Vice President, Corporate Controller, effective September 15, 2021. Ms. Clague will retain her duties as principal financial officer. Ms. Calvin will assume the principal financial officer duties from Laura Clague. Ms. Calvin has served as the Company’s Vice President, Corporate Controller since April 2018. From December 2014 through March 2018, she served as the Company’s Executive Director, Corporate Controller. From August 2012 to October 2014 she served as Director and San Diego Site Controller for Amylin Pharmaceuticals LLC, a wholly-owned subsidiary first of Bristol-Myers Squibb and then of Astrazeneca during such period.